Cardiac Safety of Trastuzumab on 185 Patients with HER2 Positive Breast Cancer
Objective To analyze the cardiac safety of trastuzumab on HER2 positive breast cancer patients. Methods Trastuzumab was administrated every three weeks in 185 patients with HER2 positive breast cancer. The initial dose was 8 mg/kg, and the subsequent dose was 6 mg/kg, for 4-36 cycles. The cardiotoxi...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2018-02-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://html.rhhz.net/ZLFZYJ/html/8578.2018.17.0975.htm |